Skip to main content
SpringerLink
Log in

Lurasidone cost saving for schizophrenia

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. British pounds

References

  1. Rajagopalan K, et al. Lurasidone in Adults with Schizophrenia in the Uk: a Cost Consequence Analysis Considering Cost Implications of Improved Efficacy and Safety. 18th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PMH14, 7 Nov 2015. Available from: URL: http://www.ispor.org/research_study_digest/list.asp?qs=42355

  2. Rajagopalan K, et al. Cost-Utility and Budget Impact Analyses Comparing Lurasidone with Aripiprazole in Adults with Schizophrenia in Scotland. 18th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PMH15, 7 Nov 2015. Available from: URL: http://www.ispor.org/research_study_digest/list.asp?qs=42356

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lurasidone cost saving for schizophrenia. PharmacoEcon Outcomes News 742, 25 (2015). https://doi.org/10.1007/s40274-015-2653-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-2653-1

Search

Navigation